All News about Bristol-Myers SquibbVia Benzinga
Bristol Myers' Deucravacitinib Scores FDA Approval For Plaque Psoriasis
September 12, 2022
Via Benzinga
Via Benzinga
Bristol Myers Squibb to Report Results for Third Quarter 2022 on October 26, 2022
September 07, 2022
From Bristol Myers Squibb
Via Business Wire
Via Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
August 23, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|